SCHEMBL961260

SCHEMBL961260

COCCN(C(=O)OC(C)(C)C)c1cc(OCc2ccccc2)cc(C=O)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.37
FGFR4 P22455 1/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
F2 P00734 2/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
GAA P10253 1/20 0.35
MAPK1 P28482 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP19A1 P11511 1/20 0.35
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
LTB4R Q15722 2/20 0.34
LTB4R2 Q9NPC1 2/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL961136 0.77 KDM4C (0.39) L3MBTL1MEN1KMT2ANPC1HTR2C
SCHEMBL959741 0.77 L3MBTL1 (0.35) L3MBTL1MEN1KMT2ANPC1F2
SCHEMBL18621043 0.75 MEN1 (0.47) L3MBTL1MEN1KMT2AKDM4EMAOB
SCHEMBL26363489 0.71 MAOB (0.57) L3MBTL1MEN1KMT2ANPC1LMNA
SCHEMBL19293611 0.71 MEN1 (0.43) L3MBTL1MEN1KMT2ALMNAMAOB
SCHEMBL14319791 0.69 MCL1 (0.54) MEN1KMT2AKDM4EMAOAMAOB
SCHEMBL17595593 0.67 MEN1 (0.39) L3MBTL1MEN1KMT2AMAOBHTR2C
SCHEMBL20049539 0.67 MAOB (0.44) F2MAOAMAOBALDH1A1
SCHEMBL25604063 0.67 HSD17B10 (0.48) MEN1KMT2ANPC1GAAALDH1A1
SCHEMBL7978965 0.67 MEN1 (0.39) L3MBTL1MEN1KMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-20 US disclosed
EP-2264026-A1 ALKYLAMINOPYRIDINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE NPY4R, NPY1R, NPY2R L3MBTL1 2460/4885MEN1 1674/4885KMT2A 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.